مباشر

BioPharma DiveCreate Medicines raises $122M to bolster in vivo CAR-T therapies FierceBiotechBioAge CEO has big plans for 'multi-disease impact' of NLRP3 drug across cardio, ocular and CNS Endpoints NewsDrugmakers have to go through rigorous tests to get a lower tariff rate FierceBiotechBiopharma leaders rally behind Pazdur for FDA commissioner pick. But does he want the role?Promega BlogCharged Molecular Glues: The Molecular Trojan Horse That Slipped Past Biology’s Toughest Bouncer Clinical OMICsContact Lenses Show Promise for Depression BioWorldFosun secures rights to Aribio’s AR-1001 in potential $4.7B deal BioPharma DiveBiogen pushing tau drug forward despite Alzheimer’s study failure Endpoints NewsDegron, CREATE, TenNor raise capital; Cabaletta posts CAR-T data Endpoints NewsAstraZeneca follows Merck with Phase 3 win in bladder cancer Endpoints NewsMacroGenics sells manufacturing arm; West Pharma discloses cybersecurity attack FierceBiotechCreate Medicines fashions $122M fundraise for in vivo CAR-T dreams

Endpoints News ١٤ مايو ٢٠٢٦

AstraZeneca follows Merck with Phase 3 win in bladder cancer

A combination of AstraZeneca's Imfinzi with Pfizer and Astellas’ Padcev kept more bladder cancer patients alive than standard of care, the company said Thursday...

A combination of AstraZeneca's Imfinzi with Pfizer and Astellas’ Padcev kept more bladder cancer patients alive than standard of care, the company said Thursday. AstraZeneca said it would seek approval for the combination, but it ...